Close

Synergy Pharma (SGYP) Reports Plecanatide Phase 2b Met Primary Objective

April 30, 2014 6:23 AM EDT Send to a Friend
Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login